University Hospital Poitiers - Hôpital Jean Bernard
Welcome,         Profile    Billing    Logout  
 7 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ROY, Lydia
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
AVAJAK, NCT05198960: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Recruiting
3
1308
Europe
Direct Oral Anticoagulants, Low-dose aspirin
University Hospital, Brest
Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients
07/27
07/27
NCT05753384: Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System

Recruiting
3
140
Europe
treatment of TKI in CML
Poitiers University Hospital
Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia
12/28
12/29
DASTOP2, NCT03573596: Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

Recruiting
2
134
Europe
Dasatinib
Amsterdam UMC, location VUmc, Uppsala University Hospital, Skane University Hospital, Helsinki University Central Hospital, Odense University Hospital, Henri Mondor University Hospital, St. Olavs Hospital, Helse Stavanger HF, Aarhus University Hospital, University Hospital, Bonn
CML, Relapsed
02/23
02/24
PONAZA, NCT03895671: : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

Recruiting
2
40
Europe
Ponatinib, Azacitidine
Versailles Hospital
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE, CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS
12/23
12/24
BosuPeg, NCT03831776: Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis

Recruiting
2
212
Europe
Bosutinib, Ropeginterferon, RoPegIFN
St. Olavs Hospital, Haukeland University Hospital, Oslo University Hospital, University Hospital of North Norway, Helse Stavanger HF, Henri Mondor University Hospital, Hôpital René Huguenin, Hôpital Mignot, Versailles Paris, Uppsala University Hospital, Odense University Hospital
Chronic Myeloid Leukemia
02/24
03/28
EPIK, NCT03481868: EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

Recruiting
N/A
160
Europe
Collection of blood and bone marrow
University Hospital, Clermont-Ferrand, Institut Paoli-Calmettes, CHRU Lille, hematology department, CH Annecy Genevois, Institut Bergonié Bordeaux, hematology department, CHU Nancy, hematology department, CHU Saint-Etienne, hematology department, Institut Universitaire du Cancer de Toulouse - Oncopole, hematology department, CHU Caen, hematology department, CHU Nice, hematology department, CHU Lyon, hematology department, AP-HP, hematology department, AP-HP Hôpital Henri-Mondor, hematology department, Versailles Hospital, Centre Leon Berard, University Hospital, Grenoble
Chronic Myeloid Leukemia (CML), Chronic Phase
05/25
02/26
BIO-TIMER, NCT06130787: Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

Recruiting
N/A
321
Europe
Blood and bone marrow sample
University Hospital, Clermont-Ferrand
Leukemia,Myeloid, Chronic
11/25
11/28
Saulnier, Pierre-Jean
MR3T - DKD, NCT04570735: MRI Biomarkers in Diabetic Kidney Disease

Completed
N/A
30
Europe
MRI
Poitiers University Hospital
Diabetic Nephropathies
01/24
01/24
ACTIDIANE, NCT03184662: Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes

Recruiting
N/A
300
Europe
HIPA, Counseling PA
Poitiers University Hospital, University Hospital, Bordeaux, University Hospital, Clermont-Ferrand, Centre Hospitalier Universitaire Dijon, Centre Hospitalier Universitaire de Besancon, Hopital Lariboisière, Bichat Hospital, Centre Hospitalier Sud Francilien, University Hospital, Lille, Centre Hospitalier Universitaire de Nice, University Hospital, Caen, University Hospital, Toulouse, University Hospital, Tours, Nantes University Hospital, Groupe Hospitalier Pitie-Salpetriere, Hospices Civils de Lyon, University Hospital, Montpellier, University Hospital, Strasbourg, Central Hospital, Nancy, France, HOSPITAL, CHARTRES, University of Liege
Type2 Diabetes, Diabetic Kidney Disease
09/23
12/23

Download Options